Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.

Ehrhardt S, Porsteinsson AP, Munro CA, Rosenberg PB, Pollock BG, Devanand DP, Mintzer J, Rajji TK, Ismail Z, Schneider LS, Baksh SN, Drye LT, Avramopoulos D, Shade DM, Lyketsos CG; S-CitAD Research Group.

Alzheimers Dement. 2019 Oct 3. pii: S1552-5260(19)35112-X. doi: 10.1016/j.jalz.2019.06.4946. [Epub ahead of print]

PMID:
31587995
2.

Improving environmental interventions for neuropsychiatric symptoms in dementia.

Kiosses DN, Rosenberg PB.

Int Psychogeriatr. 2019 Aug;31(8):1077-1080. doi: 10.1017/S104161021900098X. No abstract available.

PMID:
31469067
3.

Fornix-Region Deep Brain Stimulation-Induced Memory Flashbacks in Alzheimer's Disease.

Deeb W, Salvato B, Almeida L, Foote KD, Amaral R, Germann J, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Salloway S, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Lozano AM, Okun MS.

N Engl J Med. 2019 Aug 22;381(8):783-785. doi: 10.1056/NEJMc1905240. No abstract available.

PMID:
31433930
4.

Depression Synergy With Amyloid and Increased Risk of Cognitive Decline in Preclinical Alzheimer Disease.

Chan C, Rosenberg PB.

JAMA Netw Open. 2019 Aug 2;2(8):e198970. doi: 10.1001/jamanetworkopen.2019.8970. No abstract available.

PMID:
31397856
5.

Tetrahydrocannabinol Has Potential for Treating Agitation in Alzheimer's Disease.

Rosenberg PB, Outen JD, Amjad H, Burhanullah MH, Vandrey R, Monette PJ, Forester BP.

Am J Geriatr Psychiatry. 2019 Nov;27(11):1174-1176. doi: 10.1016/j.jagp.2019.05.014. Epub 2019 May 24. No abstract available.

PMID:
31196620
6.

Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study.

Burhanullah MH, Tschanz JT, Peters ME, Leoutsakos JM, Matyi J, Lyketsos CG, Nowrangi MA, Rosenberg PB.

Am J Geriatr Psychiatry. 2019 May 23. pii: S1064-7481(19)30368-9. doi: 10.1016/j.jagp.2019.03.023. [Epub ahead of print]

PMID:
31186157
7.

Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers.

Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM.

Alzheimers Dement (Amst). 2019 Apr 18;11:333-339. doi: 10.1016/j.dadm.2019.02.006. eCollection 2019 Dec.

8.

The Potential of Actigraphy to Assess Agitation in Dementia.

Rosenberg PB, Wanigatunga SK, Spira AP.

Am J Geriatr Psychiatry. 2019 Aug;27(8):870-872. doi: 10.1016/j.jagp.2019.03.009. Epub 2019 Mar 20. No abstract available.

PMID:
30928156
9.

Depth of sedation as an interventional target to reduce postoperative delirium: mortality and functional outcomes of the Strategy to Reduce the Incidence of Postoperative Delirium in Elderly Patients randomised clinical trial.

Sieber F, Neufeld KJ, Gottschalk A, Bigelow GE, Oh ES, Rosenberg PB, Mears SC, Stewart KJ, Ouanes JP, Jaberi M, Hasenboehler EA, Wang NY.

Br J Anaesth. 2019 Apr;122(4):480-489. doi: 10.1016/j.bja.2018.12.021. Epub 2019 Feb 4.

10.

Vestibular impairment, cognitive decline and Alzheimer's disease: balancing the evidence.

Agrawal Y, Smith PF, Rosenberg PB.

Aging Ment Health. 2019 Jan 29:1-4. doi: 10.1080/13607863.2019.1566813. [Epub ahead of print]

PMID:
30691295
11.

β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility.

Kim J, Grotegut CA, Wisler JW, Li T, Mao L, Chen M, Chen W, Rosenberg PB, Rockman HA, Lefkowitz RJ.

Skelet Muscle. 2018 Dec 27;8(1):39. doi: 10.1186/s13395-018-0184-8.

12.

Psychometric Properties of Apathy Scales in Dementia: A Systematic Review.

Mohammad D, Ellis C, Rau A, Rosenberg PB, Mintzer J, Ruthirakuhan M, Herrmann N, Lanctôt KL.

J Alzheimers Dis. 2018;66(3):1065-1082. doi: 10.3233/JAD-180485.

PMID:
30400094
13.

Depressive symptoms in relation to clinical symptom onset of mild cognitive impairment.

Chan CK, Soldan A, Pettigrew C, Wang MC, Wang J, Albert MS, Rosenberg PB; BIOCARD Research Team.

Int Psychogeriatr. 2019 Apr;31(4):561-569. doi: 10.1017/S1041610218001138. Epub 2018 Oct 10.

14.

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.

Oh ES, Blennow K, Bigelow GE, Inouye SK, Marcantonio ER, Neufeld KJ, Rosenberg PB, Troncoso JC, Wang NY, Zetterberg H, Sieber FE, Lyketsos CG.

PLoS One. 2018 Sep 25;13(9):e0204695. doi: 10.1371/journal.pone.0204695. eCollection 2018. Erratum in: PLoS One. 2018 Oct 26;13(10):e0206719.

15.

Effect of Depth of Sedation in Older Patients Undergoing Hip Fracture Repair on Postoperative Delirium: The STRIDE Randomized Clinical Trial.

Sieber FE, Neufeld KJ, Gottschalk A, Bigelow GE, Oh ES, Rosenberg PB, Mears SC, Stewart KJ, Ouanes JP, Jaberi M, Hasenboehler EA, Li T, Wang NY.

JAMA Surg. 2018 Nov 1;153(11):987-995. doi: 10.1001/jamasurg.2018.2602.

16.

Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.

Tao Y, Peters ME, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Munro CA.

Am J Alzheimers Dis Other Demen. 2018 Nov;33(7):450-457. doi: 10.1177/1533317518783278. Epub 2018 Jul 3.

PMID:
29969907
17.

Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation.

Leoutsakos JS, Yan H, Anderson WS, Asaad WF, Baltuch G, Burke A, Chakravarty MM, Drake KE, Foote KD, Fosdick L, Giacobbe P, Mari Z, McAndrews MP, Munro CA, Oh ES, Okun MS, Pendergrass JC, Ponce FA, Rosenberg PB, Sabbagh MN, Salloway S, Tang-Wai DF, Targum SD, Wolk D, Lozano AM, Smith GS, Lyketsos CG.

J Alzheimers Dis. 2018;64(2):597-606. doi: 10.3233/JAD-180121.

18.

New Clues to Preclinical Alzheimer's Disease.

Rosenberg PB, Lyketsos CG.

Am J Psychiatry. 2018 Jun 1;175(6):493-494. doi: 10.1176/appi.ajp.2018.18010048. No abstract available.

PMID:
29869544
19.

Trends and outcomes of cardiac transplantation from donors dying of drug intoxication.

Warraich HJ, Lu D, Cobb S, Cooper LB, DeVore A, Patel CB, Rosenberg PB, Schroder JN, Daneshmand MA, Milano CA, Hernandez AF, Rogers JG, Mentz RJ.

Am Heart J. 2018 May;199:92-96. doi: 10.1016/j.ahj.2018.02.003. Epub 2018 Feb 9.

PMID:
29754672
20.

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, Vozzi C, Boess F, Oh E, Lyketsos CG, Honer M, Gobbi L, Klein G, George N, Gapasin L, Kitzmiller K, Roberts J, Sevigny J, Nandi A, Brasic J, Mishra C, Thambisetty M, Mogekar A, Mathur A, Albert M, Dannals RF, Borroni E.

J Nucl Med. 2018 Dec;59(12):1869-1876. doi: 10.2967/jnumed.118.209916. Epub 2018 May 4. Erratum in: J Nucl Med. 2019 Jan;60(1):141.

21.

Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial.

Pastva AM, Duncan PW, Reeves GR, Nelson MB, Whellan DJ, O'Connor CM, Eggebeen JD, Hewston LA, Taylor KM, Mentz RJ, Rosenberg PB, Kitzman DW.

Contemp Clin Trials. 2018 Jan;64:118-127. doi: 10.1016/j.cct.2017.10.014. Epub 2017 Oct 25.

22.

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.

Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, Osorio RS, Rosenberg PB, Satlin A, Steffens D, Tariot P, Bain LJ, Carrillo MC, Hendrix JA, Jurgens H, Boot B.

Alzheimers Dement (N Y). 2017 Aug 5;3(3):440-449. doi: 10.1016/j.trci.2017.07.001. eCollection 2017 Sep. Review.

23.

Temperature-activated ion channels in neural crest cells confer maternal fever-associated birth defects.

Hutson MR, Keyte AL, Hernández-Morales M, Gibbs E, Kupchinsky ZA, Argyridis I, Erwin KN, Pegram K, Kneifel M, Rosenberg PB, Matak P, Xie L, Grandl J, Davis EE, Katsanis N, Liu C, Benner EJ.

Sci Signal. 2017 Oct 10;10(500). pii: eaal4055. doi: 10.1126/scisignal.aal4055.

24.

Sleep Disturbance, Cognitive Decline, and Dementia: A Review.

Wennberg AMV, Wu MN, Rosenberg PB, Spira AP.

Semin Neurol. 2017 Aug;37(4):395-406. doi: 10.1055/s-0037-1604351. Epub 2017 Aug 24. Review. No abstract available.

25.

Characterizing Highly Benefited Patients in Randomized Clinical Trials.

Charu V, Rosenberg PB, Schneider LS, Drye LT, Rein L, Shade D, Lyketsos CG, Frangakis CE.

Int J Biostat. 2017 May 20;13(1). pii: /j/ijb.2017.13.issue-1/ijb-2016-0045/ijb-2016-0045.xml. doi: 10.1515/ijb-2016-0045.

26.

New Insights Into Brain Mechanisms Underlying Neuropsychiatric Symptoms in Alzheimer Disease.

Rosenberg PB.

Am J Geriatr Psychiatry. 2017 Jun;25(6):580-581. doi: 10.1016/j.jagp.2017.02.023. Epub 2017 Mar 8. No abstract available.

PMID:
28408178
27.

The role of STIM1 and SOCE in smooth muscle contractility.

Feldman CH, Grotegut CA, Rosenberg PB.

Cell Calcium. 2017 May;63:60-65. doi: 10.1016/j.ceca.2017.02.007. Epub 2017 Mar 10. Review.

PMID:
28372809
28.

Clinical evaluation of brief cognitive assessment measures for patients with severe dementia.

Dixon JS, Saddington DG, Shiles CJ, Sreevalsan KP, Munro CA, Rosenberg PB.

Int Psychogeriatr. 2017 Jul;29(7):1169-1174. doi: 10.1017/S1041610217000151. Epub 2017 Mar 29.

PMID:
28351445
29.

Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.

Reeves GR, Whellan DJ, Duncan P, O'Connor CM, Pastva AM, Eggebeen JD, Hewston LA, Morgan TM, Reed SD, Rejeski WJ, Mentz RJ, Rosenberg PB, Kitzman DW; REHAB-HF Trial Investigators.

Am Heart J. 2017 Mar;185:130-139. doi: 10.1016/j.ahj.2016.12.012. Epub 2016 Dec 28.

30.

Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity.

Zhang Z, Huang TQ, Nepliouev I, Zhang H, Barnett AS, Rosenberg PB, Ou SI, Stiber JA.

Cardiooncology. 2017;3. pii: 1. doi: 10.1186/s40959-017-0020-z. Epub 2017 Jan 19.

31.

The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.

Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanctôt KL, Miller DS, Mortby ME, Onyike CU, Rosenberg PB, Smith EE, Smith GS, Sultzer DL, Lyketsos C; NPS Professional Interest Area of the International Society of to Advance Alzheimer’s Research and Treatment (NPS-PIA of ISTAART).

J Alzheimers Dis. 2017;56(3):929-938. doi: 10.3233/JAD-160979.

32.

Proceedings of the Fourth Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies.

Deeb W, Giordano JJ, Rossi PJ, Mogilner AY, Gunduz A, Judy JW, Klassen BT, Butson CR, Van Horne C, Deny D, Dougherty DD, Rowell D, Gerhardt GA, Smith GS, Ponce FA, Walker HC, Bronte-Stewart HM, Mayberg HS, Chizeck HJ, Langevin JP, Volkmann J, Ostrem JL, Shute JB, Jimenez-Shahed J, Foote KD, Wagle Shukla A, Rossi MA, Oh M, Pourfar M, Rosenberg PB, Silburn PA, de Hemptine C, Starr PA, Denison T, Akbar U, Grill WM, Okun MS.

Front Integr Neurosci. 2016 Nov 22;10:38. eCollection 2016.

33.

Loneliness as a Marker of Brain Amyloid Burden and Preclinical Alzheimer Disease.

Rosenberg PB.

JAMA Psychiatry. 2016 Dec 1;73(12):1237-1238. doi: 10.1001/jamapsychiatry.2016.2688. No abstract available.

PMID:
27806158
34.

Subtle changes in daily functioning predict conversion from normal to mild cognitive impairment or dementia: an analysis of the NACC database.

Nowrangi MA, Rosenberg PB, Leoutsakos JS.

Int Psychogeriatr. 2016 Dec;28(12):2009-2018. Epub 2016 Aug 8.

35.

A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease.

Lozano AM, Fosdick L, Chakravarty MM, Leoutsakos JM, Munro C, Oh E, Drake KE, Lyman CH, Rosenberg PB, Anderson WS, Tang-Wai DF, Pendergrass JC, Salloway S, Asaad WF, Ponce FA, Burke A, Sabbagh M, Wolk DA, Baltuch G, Okun MS, Foote KD, McAndrews MP, Giacobbe P, Targum SD, Lyketsos CG, Smith GS.

J Alzheimers Dis. 2016 Sep 6;54(2):777-87. doi: 10.3233/JAD-160017.

36.

Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.

Rosenberg PB, Lanctôt KL, Herrmann N, Mintzer JE, Porsteinsson AP, Sun X, Raman R.

J Alzheimers Dis. 2016 Aug 10;54(1):373-81. doi: 10.3233/JAD-151113.

PMID:
27567808
37.

Apathy associated with neurocognitive disorders: Recent progress and future directions.

Lanctôt KL, Agüera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, Marshall GA, Mortby ME, Onyike CU, Padala PR, Politis AM, Rosenberg PB, Siegel E, Sultzer DL, Abraham EH.

Alzheimers Dement. 2017 Jan;13(1):84-100. doi: 10.1016/j.jalz.2016.05.008. Epub 2016 Jun 27. Review.

PMID:
27362291
38.

Principal components analysis of agitation outcomes in Alzheimer's disease.

Yesavage JA, Taylor JL, Friedman L, Rosenberg PB, Lazzeroni LC, Leoutsakos JS, Kinoshita LM, Perlow MJ, Munro CA, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A; CitAD Research Group.

J Psychiatr Res. 2016 Aug;79:4-7. doi: 10.1016/j.jpsychires.2016.04.004. Epub 2016 Apr 16.

39.

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study.

Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, Frangakis C, Munro CA, Mintzer JE, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porsteinsson AP; CitAD Research Group.

Am J Psychiatry. 2016 May 1;173(5):473-80. doi: 10.1176/appi.ajp.2016.15020248. Epub 2016 Apr 1.

PMID:
27032628
40.

The Actin-Binding Protein Drebrin Inhibits Neointimal Hyperplasia.

Stiber JA, Wu JH, Zhang L, Nepliouev I, Zhang ZS, Bryson VG, Brian L, Bentley RC, Gordon-Weeks PR, Rosenberg PB, Freedman NJ.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):984-93. doi: 10.1161/ATVBAHA.115.306140. Epub 2016 Mar 24.

41.

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.

Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade D, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group.

Am J Psychiatry. 2016 May 1;173(5):465-72. doi: 10.1176/appi.ajp.2015.15050648. Epub 2016 Jan 15.

42.

Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.

Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A; CitAD Research Group.

J Psychiatr Res. 2016 Mar;74:17-21. doi: 10.1016/j.jpsychires.2015.12.005. Epub 2015 Dec 12.

43.

STIM1-Ca2+ signaling modulates automaticity of the mouse sinoatrial node.

Zhang H, Sun AY, Kim JJ, Graham V, Finch EA, Nepliouev I, Zhao G, Li T, Lederer WJ, Stiber JA, Pitt GS, Bursac N, Rosenberg PB.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):E5618-27. doi: 10.1073/pnas.1503847112. Epub 2015 Sep 30.

44.

Depression and Suicidal Ideation During Two Psychosocial Treatments in Older Adults with Major Depression and Dementia.

Kiosses DN, Rosenberg PB, McGovern A, Fonzetti P, Zaydens H, Alexopoulos GS.

J Alzheimers Dis. 2015;48(2):453-62. doi: 10.3233/JAD-150200.

45.

Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature.

McClam TD, Marano CM, Rosenberg PB, Lyketsos CG.

Harv Rev Psychiatry. 2015 Sep-Oct;23(5):377-93. doi: 10.1097/HRP.0000000000000097. Review.

PMID:
26332220
46.

Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.

Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG; CitAD Research Group.

Int Psychogeriatr. 2015 Dec;27(12):2059-67. doi: 10.1017/S1041610215001106. Epub 2015 Aug 25.

47.

Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.

Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D; CitAD Research Group.

J Geriatr Psychiatry Neurol. 2016 Mar;29(2):59-64. doi: 10.1177/0891988715601735. Epub 2015 Aug 23.

48.

STIM1 enhances SR Ca2+ content through binding phospholamban in rat ventricular myocytes.

Zhao G, Li T, Brochet DX, Rosenberg PB, Lederer WJ.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):E4792-801. doi: 10.1073/pnas.1423295112. Epub 2015 Aug 10.

49.

Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.

Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, Lyketsos CG; CitAD Research Group.

Am J Geriatr Psychiatry. 2015 Nov;23(11):1127-33. doi: 10.1016/j.jagp.2015.05.006. Epub 2015 May 19.

50.

Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow.

Daneshmand MA, Krishnamoorthy A, Samsky MD, Felker GM, Pura JA, Lokhnygina Y, Hernandez AF, Rosenberg PB, Blue LJ, Schroder JN, Rogers JG, Milano CA, Patel CB.

Am J Cardiol. 2015 Aug 15;116(4):573-9. doi: 10.1016/j.amjcard.2015.05.016. Epub 2015 May 21.

PMID:
26092273

Supplemental Content

Loading ...
Support Center